| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 6.85M | 0 |
| Revenue Growth % | - | - | - | - | -1% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 6.85M | 0 |
| Gross Margin % | - | - | - | 1% | - |
| Gross Profit Growth % | - | - | - | - | -1% |
| Operating Expenses | 10.44M | 374.87M | 212.26M | 178.14M | 201.06M |
| OpEx % of Revenue | - | - | - | 25.99% | - |
| Selling, General & Admin | 1.14M | 43.01M | 55.2M | 53.73M | 50.81M |
| SG&A % of Revenue | - | - | - | 7.84% | - |
| Research & Development | 9.3M | 96.32M | 155.08M | 124.41M | 150.24M |
| R&D % of Revenue | - | - | - | 18.15% | - |
| Other Operating Expenses | 0 | 235.54M | 1.98M | 0 | 0 |
| Operating Income | -10.44M | -374.87M | -212.26M | -171.28M | -201.06M |
| Operating Margin % | - | - | - | -24.99% | - |
| Operating Income Growth % | - | -34.91% | 0.43% | 0.19% | -0.17% |
| EBITDA | -10.29M | -374.83M | -212.13M | -170.47M | -200.11M |
| EBITDA Margin % | - | - | - | -24.88% | - |
| EBITDA Growth % | - | -35.44% | 0.43% | 0.2% | -0.17% |
| D&A (Non-Cash Add-back) | 0 | 34K | 131K | 810K | 942K |
| EBIT | -10.29M | -139.33M | -209.68M | -166.24M | -222.82M |
| Net Interest Income | -378K | -2.55M | -7.03M | 570K | 3.93M |
| Interest Income | 0 | 0 | 244K | 10.48M | 14.02M |
| Interest Expense | 378K | 2.55M | 7.28M | 9.91M | 10.09M |
| Other Income/Expense | -223K | -6.92M | -4.69M | -4.86M | -31.86M |
| Pretax Income | -10.66M | -381.79M | -216.95M | -176.14M | -232.91M |
| Pretax Margin % | - | - | - | -25.7% | - |
| Income Tax | 0 | 114K | -747K | -25.06M | 2.84M |
| Effective Tax Rate % | 1% | 1% | 1% | 0.86% | 1.01% |
| Net Income | -10.66M | -381.9M | -216.21M | -151.09M | -235.76M |
| Net Margin % | - | - | - | -22.05% | - |
| Net Income Growth % | - | -34.82% | 0.43% | 0.3% | -0.56% |
| Net Income (Continuing) | -10.66M | -381.9M | -216.21M | -151.09M | -235.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.08 | -4.24 | -2.31 | -1.57 | -2.06 |
| EPS Growth % | - | -53.57% | 0.46% | 0.32% | -0.31% |
| EPS (Basic) | -0.08 | -4.24 | -2.31 | -1.57 | -2.06 |
| Diluted Shares Outstanding | 70.89M | 89.99M | 93.4M | 96.18M | 114.47M |
| Basic Shares Outstanding | 70.89M | 89.99M | 93.4M | 96.18M | 114.47M |
| Dividend Payout Ratio | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 11.16M | 628.77M | 437.75M | 315.09M | 536.41M |
| Cash & Short-Term Investments | 7.23M | 595.08M | 393.64M | 256.55M | 482.18M |
| Cash Only | 7.23M | 595.08M | 393.64M | 128.03M | 383.22M |
| Short-Term Investments | 0 | 0 | 0 | 128.52M | 98.96M |
| Accounts Receivable | 0 | 16.81M | 26.72M | 39.15M | 45.3M |
| Days Sales Outstanding | - | - | - | 2.09K | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 3.93M | 993K | 3.27M | 1.62M | 1.78M |
| Total Non-Current Assets | 552K | 861K | 6.56M | 45.15M | 40.39M |
| Property, Plant & Equipment | 0 | 162K | 1.17M | 12.95M | 11.76M |
| Fixed Asset Turnover | - | - | - | 0.53x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 552K | 699K | 1.88M | 2.55M | 2.05M |
| Total Assets | 11.72M | 629.63M | 444.31M | 360.25M | 576.8M |
| Asset Turnover | - | - | - | 0.02x | - |
| Asset Growth % | - | 52.74% | -0.29% | -0.19% | 0.6% |
| Total Current Liabilities | 8.62M | 24.64M | 38.34M | 39.38M | 58M |
| Accounts Payable | 1.03M | 8.06M | 13.84M | 11.81M | 7.14M |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 5.63M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 922K | 4.97M | 7.95M | 839K | 10.18M |
| Current Ratio | 1.30x | 25.52x | 11.42x | 8.00x | 9.25x |
| Quick Ratio | 1.30x | 25.52x | 11.42x | 8.00x | 9.25x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 113.44M | 69.8M | 84.62M | 117.25M |
| Long-Term Debt | 0 | 75.7M | 69.8M | 75.7M | 108.94M |
| Capital Lease Obligations | 0 | 0 | 0 | 8.89M | 8.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 37.74M | 0 | 29K | 29K |
| Total Liabilities | 8.62M | 138.08M | 108.14M | 124M | 175.25M |
| Total Debt | 5.63M | 75.7M | 69.8M | 84.59M | 117.23M |
| Net Debt | -1.6M | -519.38M | -323.84M | -43.44M | -266M |
| Debt / Equity | 1.82x | 0.15x | 0.21x | 0.36x | 0.29x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -27.62x | -147.08x | -29.17x | -17.29x | -19.93x |
| Total Equity | 3.1M | 491.55M | 336.17M | 236.24M | 401.55M |
| Equity Growth % | - | 157.67% | -0.32% | -0.3% | 0.7% |
| Book Value per Share | 0.04 | 5.46 | 3.60 | 2.46 | 3.51 |
| Total Shareholders' Equity | 3.1M | 491.55M | 336.17M | 236.24M | 401.55M |
| Common Stock | 25.55M | 252K | 265K | 273K | 359K |
| Retained Earnings | -23.84M | -385.65M | -601.86M | -752.95M | -988.7M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 572K | 688K | -1.5M | 1.49M | 4.21M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | -10.63M | -136.14M | -200.55M | -160.34M | -142.06M |
| Operating CF Margin % | - | - | - | -23.4% | - |
| Operating CF Growth % | - | -11.81% | -0.47% | 0.2% | 0.11% |
| Net Income | -10.66M | -381.85M | -216.21M | -151.09M | -235.76M |
| Depreciation & Amortization | 0 | 33.99K | 131K | 810K | 942K |
| Stock-Based Compensation | 336K | 0 | 24.96M | 29.39M | 33.55M |
| Deferred Taxes | 0 | 0 | -2.86M | -26.63M | 2.65M |
| Other Non-Cash Items | 186K | 251.06M | -3.75M | 6.03M | 34.46M |
| Working Capital Changes | -489K | -5.38M | -2.83M | -18.86M | 22.1M |
| Change in Receivables | -1.46M | -6.72M | -11.71M | 0 | -6.6M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -49K | 0 | 6.35M | -2.73M | -4.58M |
| Cash from Investing | 0 | 63.25M | -931K | -127M | 31.27M |
| Capital Expenditures | 0 | -185.98K | -1.14M | -169K | -34K |
| CapEx % of Revenue | - | - | - | 0.02% | - |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 206K | 0 | 0 |
| Cash from Financing | 1.36M | 660.07M | 457K | 21.12M | 364.75M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - |
| Other Financing | 1K | 0 | 457K | 310K | 5.91M |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | -10.63M | -136.33M | -201.68M | -160.51M | -142.09M |
| FCF Margin % | - | - | - | -23.42% | - |
| FCF Growth % | - | -11.82% | -0.48% | 0.2% | 0.11% |
| FCF per Share | -0.15 | -1.51 | -2.16 | -1.67 | -1.24 |
| FCF Conversion (FCF/Net Income) | 1.00x | 0.36x | 0.93x | 1.06x | 0.60x |
| Interest Paid | 0 | 0 | 7.28M | 9.91M | 10.09M |
| Taxes Paid | 0 | 0 | 1.3M | 2.94M | 82K |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -344.19% | -154.41% | -52.24% | -52.79% | -73.93% |
| Return on Invested Capital (ROIC) | - | - | -1291.66% | -125.25% | -91.85% |
| Gross Margin | - | - | - | 100% | - |
| Net Margin | - | - | - | -2204.65% | - |
| Debt / Equity | 1.82x | 0.15x | 0.21x | 0.36x | 0.29x |
| Interest Coverage | -27.62x | -147.08x | -29.17x | -17.29x | -19.93x |
| FCF Conversion | 1.00x | 0.36x | 0.93x | 1.06x | 0.60x |
| Revenue Growth | - | - | - | - | -100% |
| 2021 | |
|---|---|
| Lixivaptan | 200M |
| Lixivaptan Growth | - |
Centessa Pharmaceuticals plc (CNTA) reported $15.0M in revenue for fiscal year 2024.
Centessa Pharmaceuticals plc (CNTA) saw revenue decline by 100.0% over the past year.
Centessa Pharmaceuticals plc (CNTA) reported a net loss of $242.7M for fiscal year 2024.
Centessa Pharmaceuticals plc (CNTA) has a return on equity (ROE) of -73.9%. Negative ROE indicates the company is unprofitable.
Centessa Pharmaceuticals plc (CNTA) had negative free cash flow of $181.2M in fiscal year 2024, likely due to heavy capital investments.